iPSC-Derived Airway Epithelial Cells: Progress, Promise, and Challenges.

Area of Science:

• Regenerative Medicine
• Stem Cell Biology
• Pulmonary Research

Background:

• Induced pluripotent stem cells (iPSCs) are derived from somatic cells and can be expanded indefinitely in vitro.
• iPSCs hold promise as an unlimited cell source for generating various cell types, including lung progenitor cells.
• Pulmonary regenerative medicine aims to repair or replace damaged lung tissue.

Approach:

• This review comprehensively surveys recent advancements in utilizing iPSCs for generating proximal and distal airway epithelial cells.
• The generation of mixed lung organoids from iPSCs is also discussed.
• The review focuses on the technological challenges impeding the clinical translation of iPSC-based therapies.

Key Points:

• iPSCs can be differentiated into lung progenitor cells, offering a potential therapeutic strategy.
• Generating airway epithelial cells and lung organoids from iPSCs is a key area of research.
• Significant technological hurdles remain before iPSC-derived therapies can be clinically applied.

Conclusions:

• iPSCs represent a powerful tool for advancing pulmonary regenerative medicine.
• Further research and technological innovation are crucial for overcoming challenges in clinical translation.
• The potential of iPSCs in treating lung diseases is substantial but requires continued development.